Drug Trial Radar · NCT04377555
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab
Last checked: Nov 20, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
179
Actual
Start
Jul 30, 2020
Primary completion
Dec 15, 2022
Study completion Nov 11, 2025
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identified Black or African American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment with Ocrelizumab. The study plans to enroll approximately 150 participants (75 AA and 75 HA) with 50 participants enrolled in a CSF sub-study.
Conditions
- Multiple Sclerosis, Relapsing
Interventions
OcrelizumabDrug
Ocrelizumab will be administered intravenously (IV) at a dose of 600 mg every 24 weeks. The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent dose, ocrelizumab will be administered as a single 600 mg IV infusion every 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Free of Any Protocol-defined Events During a 48-week Period on TreatmentTime frame: 48 Weeks
Locations
28 sites in 3 countries. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona
Keck School of Medicine of USC
Los Angeles, California
Georgetown University Medical Center
Washington D.C., District of Columbia
Baptist Neurology - Beaches
Jacksonville Beach, Florida
University of Miami Miller School of Medicine
Miami, Florida
Shepherd Center Inc.
Atlanta, Georgia
Atlanta Neuroscience Institute
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
University of Chicago
Chicago, Illinois
Josephson Wallack Munshower Neurology PC
Indianapolis, Indiana
University of Maryland Medical Center
Baltimore, Maryland
Johns Hopkins University Neurology Research Office
Baltimore, Maryland
Wayne State University
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
Hackensack University Medical Center
Paramus, New Jersey
SUNY Upstate Medical Center
Syracuse, New York
Guilford Neurologic Research Partners, LLC
Greensboro, North Carolina
Jefferson University Hospitals, Thomas Jefferson University
Philadelphia, Pennsylvania
Neurology Clinic - Cordova
Cordova, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
North Texas Institute of Neurology and Headache NextStage Clinical Research Clinic
Frisco, Texas
Baylor College of Medicine Medical Center
Houston, Texas
Multiple Sclerosis Center of Tidewater
Norfolk, Virginia
Wheaton Franciscan Healthcare - St. Francis Outpatient Center
Milwaukee, Wisconsin
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin
The Aga Khan University-Kenya.
Nairobi, Kenya
Centro Internacional De Mercadeo
Guaynabo, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.